The work being done as a result of the grants in this new funding cycle will have an incredible impact on the world of PD. -- Leslie A. Chambers, President & CEO of APDA
NEW YORK, NY (PRWEB) September 06, 2018
The American Parkinson Disease Association (APDA) has awarded more than $1.7 million to support cutting-edge Parkinson’s disease (PD) research in the form of: a prestigious George C. Cotzias Fellowship, two Post-Doctoral Fellowships, 11 Research Grants, and eight APDA Centers for Advanced Research, as part of its 2018-2019 funding cycle. With someone diagnosed with PD every nine minutes, this research is critical as we push for better treatments and ultimately, a cure.
The grants are awarded through a competitive application process and reviewed by APDA’s Scientific Advisory Board (SAB) which is comprised of scientists with a wide array of backgrounds and expertise in all areas relevant to PD research. The SAB meets annually to review all grant proposals and set the scientific direction of APDA’s annual research investment. Their focus is to identify researchers early in their careers and attract them to the PD field, as well as to help established investigators pursue new and novel ideas. In many cases these projects produce significant pilot data, which has enabled researchers to apply for and receive multimillion dollar research grants from the National Institutes of Health and other funding institutions.
“It is vital to accelerate research and support translational ideas that can lead to new treatments for those people living with PD,” commented David G. Standaert, MD, PhD, John N. Whitaker Professor, Chair of Neurology at the University of Alabama at Birmingham, School of Medicine and Chairman of the SAB. “APDA’s SAB is focused on investing in the best science to support that important mission.”
“APDA is funding an exciting array of projects this year”, said Rebecca Gilbert, MD, PhD, Vice President and Chief Scientific Officer, APDA. “Our funding support will help investigate new biomarkers of Parkinson’s disease, examine the scientific basis for gender differences in PD, and probe the differences in PD among people of varying ethnicities, among many other worthy projects that will have an impact on the future of PD research”.
The George C. Cotzias Fellowship is awarded to a young physician-scientist with exceptional promise. The award spans three years and is designed to fund a long-range project focused on PD. This year’s awardee is:
- - Aasef Shaikh, MBBS, PhD, Cleveland VA Medical Center and Case Western Reserve University, Cleveland, OH, who will investigate the influence of basal ganglia, thalamus, and cerebellum network on discordant visual input induced gait disorder in PD. The project will aim to understand how PD interferes in the brain pathways that maintain gait and balance.
Post-Doctoral Fellowships are awarded to support post-doctoral scientists whose research holds promise to provide new insights into the pathophysiology, etiology and treatment of PD. This year’s awardees are:
- - Daniel Joyce, PhD, Stanford University, Stanford, CA, who will study pupil-based biomarkers of PD.
- - Giulietta Riboldi, MD, New York University School of Medicine, New York, NY, who will research the role of GBA mutations in the pathogenesis of PD.
Research Grants are awarded to investigators performing innovative PD research at major academic institutions across the United States. This year’s awardees and their areas of study are as follows:
- - Tim Bartels, PhD, The Brigham and Women’s Hospital, Boston, MA: Alpha-synuclein related lipid pathology in PD
- - Christopher Bishop, PhD, Binghamton University, Binghamton, NY: Targeting the Pedunculopontine Tegmental Nucleus to optimize treatment of PD
- - Shu Chen, PhD, Case Western Reserve University, Cleveland, OH: Novel knockin models linking Rab phosphorylation to neurodegeneration in PD
- - Elizabeth Disbrow, PhD, Louisiana State University Health Sciences Center, Shreveport, LA: Diversity in biomarker discovery
- - Yuanfang Guan, PhD, University of Michigan, Ann Arbor, MI: Digital biomarkers for monitoring PD
- - Mallory Hacker, PhD, Vanderbilt University Medical Center, Nashville, TN: Investigating long-term clinical outcomes of Subthalamic Nucleus Deep Brain Stimulation in early-stage PD
- - Magdalena Ivanova, PhD, University of Michigan, Ann Arbor, MI: Biochemical and structural studies of alpha-synuclein fibrils derived from brain tissues with PD and dementia with Lewy bodies with Alzheimer’s disease
- - Cameron Jeter, PhD, The University of Texas Health Science Center, Houston, TX: Protective role of the oral microbiome in PD
- - Eunsung Junn, PhD, Rutgers, The State University of New Jersey, Piscataway, NJ: In vivo identification of microRNAs associated with alpha-synuclein mRNA
- - Roberta Marongiu, PhD, Weill Cornell Medical College, New York, NY: Menopause as an important transition state in the susceptibility• to PD
- - Talene Yacoubian, MD, PhD, University of Alabama at Birmingham School of Medicine, Birminham, AL: Rab27b as a potential regulator of alpha-synuclein spread
APDA Centers for Advanced Research support large PD research programs which include research trainees, fellowship programs, early-stage discovery programs and later-stage clinical translation. These Centers facilitate research which is at the forefront of investigation into the cause, treatment and ultimately cure for PD. This year, two new Centers were chosen through a competitive application process. The current APDA Centers for Advanced Research are:
- - Boston University School of Medicine, Boston, MA
- - Emory University School of Medicine, Atlanta, GA
- - Mayo Clinic, Jacksonville, FL (new)
- - Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
- - The Brigham and Women’s Hospital, Boston, MA (new)
- - University of Alabama at Birmingham School of Medicine, Birmingham, AL
- - University of Pittsburgh Medical Center, Pittsburgh, PA
- - Washington University School of Medicine, St. Louis, MO
Learn more about these grantees and the exciting work they are doing and browse all APDA-funded research by visiting https://www.apdaparkinson.org/research/what-we-fund/.
“The work being done as a result of the grants in this new funding cycle will have an incredible impact on the world of PD,” stated Leslie A. Chambers, President & CEO of APDA. “This work is only possible because of the steadfast support of our generous APDA donors.”
Researchers and physicians who are interested in applying for APDA funding can visit for details on the 2019-2020 funding opportunities.
The American Parkinson Disease Association (APDA) is the largest grassroots network dedicated to fighting Parkinson’s disease (PD) and works tirelessly to assist the more than 1 million Americans with PD live life to the fullest in the face of this chronic, neurological disorder. Founded in 1961, APDA has raised and invested more than $177 million to provide outstanding patient services and educational programs, elevate public awareness about the disease, and support research designed to unlock the mysteries of PD and ultimately put an end to this disease. To join us in the fight against Parkinson’s disease and to learn more about the support APDA provides nationally through our network of Chapters and Information & Referral (I&R) Centers, as well as our national Research Program and Centers for Advanced Research, please visit us at http://www.apdaparkinson.org.
TO VIEW APDA'S RESEARCH VIDEO, CLICK HERE.
# # #